Flagellated bacterial porter for in situ tumor vaccine
Authors:Haiheng Xu1, Yiqiao Hu1, 2 and Jinhui Wu1, 2, 3
doi: 10.15698/mic2022.09.784
Volume 9, pp. 158 to 161, published 24/08/2022.
1 State Key Laboratory of Pharmaceutical Biotechnology, Medical School of Nanjing University & School of Life Sciences, Nanjing University, Nanjing 210093, China.
2 Jiangsu Provincial Key Laboratory for Nano Technology, Nanjing University, Nanjing 210093, China.
3 Chemistry and Biomedicine Innovation Center, Nanjing University, Nanjing 210023, China.
Keywords:
flagellate bacteria, antigen presentation, transport antigen, tumor vaccine, tumor periphery, dendritic cell, abscopal effect
Corresponding Author(s):
Conflict of interest statement:
The authors declare no conflict of interest.
Please cite this article as:
Haiheng Xu, Yiqiao Hu and Jinhui Wu (2022). Flagellated bacterial porter for in situ tumor vaccine. Microbial Cell: 9(9): 158-161. doi: 10.15698/mic2022.09.784
© 2022 Xu et al. This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the original author and source are acknowledged.
Abstract:
Cancer immunotherapy, which use the own immune system to attack tumors, are increasingly popular treatments. But, due to the tumor immunosuppressive microenvironment, the antigen presentation in the tumor is limited. Recently, a growing number of people use bacteria to stimulate the body’s immunity for tumor treatment due to bacteria themselves have a variety of elements that activate Toll-like receptors. Here, we discuss the use of motility of flagellate bacteria to transport antigens to the tumor periphery to activate peritumoral dendritic cells to enhance the effect of in situ tumor vaccines.